Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with HER2 mutations and amplification may benefit from HER2-targeted therapy, including afatinib. However, the data regarding the clinical activity of afatinib in Chinese patients with NSCLC harboring HER2 alterations are limited. PATIENTS AND...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Song, Zhengbo, Lv, Dongqing, Chen, Shiqing, Huang, Jianhui, Wang, Liping, Xu, Shuguang, Chen, Huafei, Wang, Guoqiang, Lin, Quan
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2021
主題:
Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138059/
https://ncbi.nlm.nih.gov/pubmed/34026634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.657283
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料